Literature DB >> 33830788

Validation of a Mortality Composite Score in the Real-World Setting: Overcoming Source-Specific Disparities and Biases.

Michelle H Lerman1, Benjamin Holmes1, Daniel St Hilaire1, Mary Tran1, Matthew Rioth1, Vinod Subramanian1, Alissa M Winzeler1, Thomas Brown1.   

Abstract

PURPOSE: This study tested whether a composite mortality score could overcome gaps and potential biases in individual real-world mortality data sources. Complete and accurate mortality data are necessary to calculate important outcomes in oncology, including overall survival. However, in the United States, there is not a single complete and broadly applicable mortality data source. It is further likely that available data sources are biased in their coverage of sex, race, age, and socioeconomic status (SES).
METHODS: Six individual real-world data sources were combined to develop a high-quality composite mortality score. The composite score was benchmarked against the gold standard for mortality data, the National Death Index. Subgroup analyses were then conducted to evaluate the completeness and accuracy by sex, race, age, and SES.
RESULTS: The composite mortality score achieved a sensitivity of 94.9% and specificity of 92.8% compared with the National Death Index, with concordance within 1 day of 98.6%. Although some individual data sources show significant coverage gaps related to sex, race, age, and SES, the composite score maintains high sensitivity (84.6%-96.1%) and specificity (77.9%-99.2%) across subgroups.
CONCLUSION: A composite score leveraging multiple scalable sources for mortality in the real-world setting maintained strong sensitivity, specificity, and concordance, including across sex, race, age, and SES subgroups.

Entities:  

Mesh:

Year:  2021        PMID: 33830788      PMCID: PMC8140809          DOI: 10.1200/CCI.20.00143

Source DB:  PubMed          Journal:  JCO Clin Cancer Inform        ISSN: 2473-4276


  10 in total

Review 1.  A primer and comparative review of major US mortality databases.

Authors:  Diane C Cowper; Joseph D Kubal; Charles Maynard; Denise M Hynes
Journal:  Ann Epidemiol       Date:  2002-10       Impact factor: 3.797

2.  Identifying a national death index match.

Authors:  Gerda G Fillenbaum; Bruce M Burchett; Dan G Blazer
Journal:  Am J Epidemiol       Date:  2009-06-30       Impact factor: 4.897

3.  I am Not Dead Yet: Identification of False-Positive Matches to Death Master File.

Authors:  Alexander Turchin; Maria Shubina; Shawn N Murphy
Journal:  AMIA Annu Symp Proc       Date:  2010-11-13

4.  An evaluation of the Social Security Administration master beneficiary record file and the National Death Index in the ascertainment of vital status.

Authors:  D N Wentworth; J D Neaton; W L Rasmussen
Journal:  Am J Public Health       Date:  1983-11       Impact factor: 9.308

Review 5.  Enrollment of Racial Minorities in Clinical Trials: Old Problem Assumes New Urgency in the Age of Immunotherapy.

Authors:  Bassel Nazha; Manoj Mishra; Rebecca Pentz; Taofeek K Owonikoko
Journal:  Am Soc Clin Oncol Educ Book       Date:  2019-05-17

6.  Test of the National Death Index and Equifax Nationwide Death Search.

Authors:  J W Rich-Edwards; K A Corsano; M J Stampfer
Journal:  Am J Epidemiol       Date:  1994-12-01       Impact factor: 4.897

7.  Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018.

Authors:  Jonathan M Loree; Seerat Anand; Arvind Dasari; Joseph M Unger; Anirudh Gothwal; Lee M Ellis; Gauri Varadhachary; Scott Kopetz; Michael J Overman; Kanwal Raghav
Journal:  JAMA Oncol       Date:  2019-10-10       Impact factor: 31.777

8.  Accuracy and completeness of mortality data in the Department of Veterans Affairs.

Authors:  Min-Woong Sohn; Noreen Arnold; Charles Maynard; Denise M Hynes
Journal:  Popul Health Metr       Date:  2006-04-10

Review 9.  The impact of socioeconomic status on access to cancer clinical trials.

Authors:  K Sharrocks; J Spicer; D R Camidge; S Papa
Journal:  Br J Cancer       Date:  2014-08-05       Impact factor: 7.640

10.  Development and Validation of a High-Quality Composite Real-World Mortality Endpoint.

Authors:  Melissa D Curtis; Sandra D Griffith; Melisa Tucker; Michael D Taylor; William B Capra; Gillis Carrigan; Ben Holzman; Aracelis Z Torres; Paul You; Brandon Arnieri; Amy P Abernethy
Journal:  Health Serv Res       Date:  2018-05-14       Impact factor: 3.402

  10 in total
  2 in total

1.  Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network.

Authors:  Jeanna Wallenta Law; Debanjali Mitra; Henry G Kaplan; Tamuno Alfred; Adam M Brufsky; Birol Emir; Haley McCracken; Xianchen Liu; Ronda G Broome; Chenan Zhang; Caroline DiCristo; Connie Chen
Journal:  Curr Oncol       Date:  2022-02-12       Impact factor: 3.677

2.  The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies.

Authors:  Donna R Rivera; Henry J Henk; Elizabeth Garrett-Mayer; Jennifer B Christian; Andrew J Belli; Suanna S Bruinooge; Janet L Espirito; Connor Sweetnam; Monika A Izano; Yanina Natanzon; Nicholas J Robert; Mark S Walker; Aaron B Cohen; Marley Boyd; Lindsey Enewold; Eric Hansen; Rebecca Honnold; Lawrence Kushi; Pallavi S Mishra Kalyani; Ruth Pe Benito; Lori C Sakoda; Elad Sharon; Olga Tymejczyk; Emily Valice; Joseph Wagner; Laura Lasiter; Jeff D Allen
Journal:  Clin Pharmacol Ther       Date:  2021-11-11       Impact factor: 6.903

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.